A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- SUVmax of FDG in Each Colonic Segment
研究概览
简要总结
Patients who undergo PET-CT scans to look for cancer are given an intravenous contrast (FDG) that is taken-up by active cells such as cancer cells. This contrast can then be seen in the body using the PET-CT scanner. However, cells in the colon also take up the FDG, and can produce "false positive" signals from the colon. Our hypothesis is that much of this signal comes from bacteria that are present in high concentrations in the colon. If this is the case, using an antibiotic to suppress the activity of bacteria may improve the ability of PET-CT to distinguish abnormal cells from normal cells in the colon.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients undergoing clinically-indicated PET-CT scan for non-GI lymphoma
排除标准
- •Patients with known Inflammatory Bowel Disease
- •Patients with known colon cancer
研究组 & 干预措施
Rifaximin
干预措施: Rifaximin (Drug)
结局指标
主要结局
SUVmax of FDG in Each Colonic Segment
时间窗: Day 2
次要结局
- SUVavg in Each Colonic Segment(Day 2)
研究者
Alan C. Moss
Assistant Professor of Medicine
Beth Israel Deaconess Medical Center
